Author:
Tyszczuk-Rotko Katarzyna,Staniec Katarzyna,Sztanke Krzysztof,Sztanke Małgorzata
Abstract
AbstractDimethyl 2-[2-(1-phenyl-4,5-dihydro-1H-imidazol-2-yl)hydrazinylidene]butanedioate (DIHB) and 8-(3-chlorophenyl)-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione (HDIT) are promising candidates for anticancer agents, the first analytical procedures of which are presented in this paper. The commercially available unmodified glassy carbon electrode (GCE) was used as a sensor for the individual and simultaneous differential pulse voltammetric (DPV) determination of these possible anticancer drugs. The findings concerning the electrochemical behaviour indicated that DIHB and HDIT display at GCE, as a sensor, the oxidation peaks at 1.18 and 0.98 V, respectively (vs. Ag/AgCl, 3.0 mol L−1 KCl) in the 0.125 mol L−1 acetate buffer of pH = 4.5, which were employed for their quantification. Various experimental parameters were carefully investigated, to achieve high sensitivity in voltammetric measurements. Finally, under the optimised conditions (t of 60 s, ΔEA of 75 mV, ν of 225 mV s−1, and tm of 2 ms), the proposed DPV procedure with the GCE demonstrated broad linear sensing ranges (1–200 nmol L−1—DIHB and 5–200 nmol L−1—HDIT), boasting the detection limits of 0.18 nmol L−1 for DIHB and 1.1 nmol L−1 for HDIT. Moreover, the developed procedure was distinguished by good selectivity, repeatability of DIHB and HDIT signals and sensor reproducibility. The practical application of this method was demonstrated by analysing the urine reference material without any prior treatment. The results showed that this environmentally friendly approach, with a modification-free sensor, is suitable for the sensitive, selective and rapid quantification of DIHB and HDIT.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Sztanke, K. & Tkaczyński, T. (inventors). Medical University of Lublin (assignee). Preparation of new dimethyl esters of 2-[(1-aryl-Δ2-imidazolin-2-ylhydrazono]succinic acids. Polish Patent, PL 188616 (2005).
2. Worzakowska, M., Sztanke, M., Rzymowska, J. & Sztanke, K. Thermal decomposition path—studied by the simultaneous thermogravimetry coupled with Fourier transform infrared spectroscopy and quadrupole mass spectrometry—of imidazoline/dimethyl succinate hybrids and their biological characterization. Materials 16, 4638 (2023).
3. Sztanke, K., Matosiuk, D. & Fidecka, S. (inventors). Medical University of Lublin (assignee). New 3-hydroxy-4-oxo-8-aryl-7,8-dihydro-6H-imidazo[2,1-c][1,2,4]triazines and method for their manufacture. Polish Patent, PL 196752 (2008).
4. Sztanke, K. et al. Antinociceptive activity of new imidazolidine carbonyl derivatives. Part 4. Synthesis and pharmacological activity of 8-aryl-3,4-dioxo-2H,8H–6,7-dihydroimidazo[2,1-c][1,2,4]triazines. Eur. J. Med. Chem. 40, 127–134 (2005).
5. Martiskainen, O., Sztanke, K., Matosiuk, D. & Pihlaja, K. Electron ionization mass spectra of 8-aryl-3,4-dioxo-2H,8H–6,7-dihydroimidazo[2,1-c][1,2,4]triazines. Do they exhibit tautomerism in the gas phase? Rapid Commun. Mass Spectrom. 20, 2548–2552 (2006).